MEDI9253 + durvalumab

This combination therapy consists of two investigational and approved agents, respectively: **MEDI9253** is an experimental, recombinant oncolytic virus derived from Newcastle disease virus and engineered to encode human interleukin-12 (IL-12), a pro-inflammatory cytokine that stimulates both innate and adaptive anti-tumor immune responses. MEDI9253 selectively replicates in tumor cells, leading to direct oncolysis and localized immune stimulation. **Durvalumab** is a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death-ligand 1 (PD-L1), thereby potentiating antitumor T cell activity by preventing PD-L1 from inhibiting cytotoxic T-cell function. The combination is designed to promote innate immune activation (via IL-12), direct tumor lysis (oncolytic virus), and enhanced adaptive antitumor immunity (checkpoint blockade). This combination is in early clinical development for select advanced/metastatic solid tumors, such as melanoma, microsatellite-stable colorectal cancer, and renal cell carcinoma, aiming to assess safety, biological activity, and potential synergy[1][3][5].

Brand names

Imfinzi (for durvalumab)